Science

Potential vaccine against Covid-19 by US scientists develop immunity in mice

Prashasti Awasthi Mumbai | Updated on April 03, 2020 Published on April 03, 2020

File photo

The United States scientists on Thursday informed that preliminary tests of the potential vaccine against the coronavirus on mice have shown that it can induce an immune response that is capable to prevent the virus, Reuters reported.

A team at the University of Pittsburgh School of Medicine in US mentioned that they were able to move quickly in developing a potential Covid-19 vaccine after having an idea of other coronaviruses that cause Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).

According to Andrea Gambotto, an associate professor at Pittsburgh, the two viruses, which are closely related to SARS-CoV-2 (the new coronavirus causing the Covid-19 pandemic), teach that a particular protein, called a spike protein, is important for inducing immunity against the virus. “We knew exactly where to fight this new virus,” said Gambotto to Reuters.

The prototype vaccine called PittCoVacc, which has been tested on mice, generated what they described as “a surge of antibodies” against the new coronavirus within two weeks.

However, the scientists cautioned that since the testing is on the initial stage, animals have not been tracked for very long as yet. Hence, it is too early to comment on how long the immunity against the coronavirus would last.

But they speculated that tests in mice with their MERS experimental vaccine must have produced a sufficient level of antibodies to neutralize the virus for at least a year, Reuters report added.

The team said they hope to start testing the vaccine candidate on people in clinical trials in the next few months.

The potential vaccine uses a needle patch design, called a microneedle array, to increase its potential potency.

This array is a fingertip-sized patch of 400 tiny needles made out of sugar and the spike protein, Gambotto explained. It is designed to deliver the spike protein pieces into the skin, where the immune reaction is strongest, as per the Reuters report.

Meanwhile, researchers around the world are trying to develop potential treatments or vaccines against the deadly novel coronavirus that has claimed the lives of nearly 47,000 people and infected almost a million in just a few months.

Published on April 03, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.